BridgeBio Pharma, Inc. (BBIO) SEC filings

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.17−1.37 (-1.72%)

Close on Nov 12, 2026Market cap $15.23BP/E –Yield –

SEC filings

40 of BridgeBio Pharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 6, 2026	Oct 13, 2026	SEC EDGAR
Current report	8-K	Aug 31, 2026	Aug 31, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 17, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	8-K	Jul 1, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 26, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 8, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 22, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Mar 30, 2026	Mar 30, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 24, 2026	SEC EDGAR
Current report	8-K	Feb 24, 2026	Feb 24, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Jan 14, 2026	Jan 21, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 27, 2025	Oct 27, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Aug 5, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Jun 27, 2025	Jul 2, 2025	SEC EDGAR
Current report	8-K	Jun 20, 2025	Jun 23, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 20, 2025	Apr 30, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Apr 29, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Mar 17, 2025	Mar 17, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 28, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 20, 2025	SEC EDGAR
Current report	8-K	Feb 20, 2025	Feb 20, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Nov 22, 2024	Nov 25, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBIO.

Compare: BBIO vs KNSA · BBIO vs IONS · BBIO vs INSM · BBIO vs SRPT · BBIO vs PTCT

Revenue growth167.3% · median -0.7%

Gross margin94.3% · median 90.2%

Operating margin-38.5% · median -2.5%

Company	Revenue	Growth
SRPT	$1.96B	-18.9%
INSM	$1.52B	+240.0%
PTCT	$1.16B	-35.1%
IONS	$960.09M	-0.7%
KNSA	$945.96M	+58.2%
BBIO	$945.54M	+167.3%

Company

Next earnings (est.): Feb 23, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 834
Held by institutions: 99.4%
Auditor: Deloitte & Touche LLP
SEC CIK: 1743881

Advertisement
300 × 250

See a number that looks wrong?